Authors’ Reply to the Letter to the Editor by Kim et al: Are We Asking the Right Question for New Biomarkers – “Ready for Prime Time” Versus Demonstrated Clinical Utility?

Authors:
Bennett A. Caughey Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA

Search for other papers by Bennett A. Caughey in
Current site
Google Scholar
PubMed Close
 MD
and
Aparna R. Parikh Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA

Search for other papers by Aparna R. Parikh in
Current site
Google Scholar
PubMed Close
 MD
Volume/Issue:
Volume 23: Issue 5
Online Publication Date:
May 2025
DOI:
https://doi.org/10.6004/jnccn.2025.7041
Restricted access
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Kim GY, Tie J, Gibbs P. Are we asking the right question for new biomarkers – “ready for prime time” versus demonstrated clinical utility? J Natl Compr Canc Netw 2025;23:e257037.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Caughey BA, Parikh AR. ctDNA/MRD testing for colon cancer: a work in progress or ready for prime-time standard of care? J Natl Compr Canc Netw 2024;22:e247049.

  • 3.

    Tie J, Cohen JD, Lahouel K, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med 2022;386:2261–2272.

  • 4.

    Yukami H, Nakamura Y, Mishima S, et al. Circulating tumor DNA (ctDNA) dynamics in patients with colorectal cancer (CRC) with molecular residual disease: updated analysis from GALAXY study in the CIRCULATE-JAPAN. J Clin Oncol 2024;42(Suppl):Abstract 6.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Bando H, Watanabe J, Kotaka M, et al. A randomized, double-blind, phase III study comparing trifluridine/tipiracil (FTD/TPI) versus placebo in patients with molecular residual disease following curative resection of colorectal cancer (CRC): the ALTAIR study. J Clin Oncol 2025;43(Suppl):Abstract LBA22.

    • PubMed
    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2025 by the National Comprehensive Cancer Network 2025
Article Category:
Reply
Print Publication Date:
01 May 2025
Online Publication Date:
May 2025

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 141 141 141
PDF Downloads 46 46 46
EPUB Downloads 0 0 0